Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis

Minori Miyake-Kashima, Yoji Takano, Mari Tanaka, Yoshiyuki Satake, Tetsuya Kawakita, Murat Dogru, Naoko Asano-Kato, Kazumi Fukagawa, Hiroshi Fujishima

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: We compared the efficacy of a new nonsteroidal antiinflammatory drug (NSAID) eye drop, 0.1% bromfenac sodium (Bromfenac), with that of an antiallergic agent, 0.1% pemirolast potassium (Pemirolast), in the treatment of seasonal allergic conjunctivitis in Japanese patients. Methods: Twenty-two subjects with seasonal allergic conjunctivitis were enrolled in the study. One eye was treated with Bromfenac eye drops and the contralateral eye was treated with Pemirolast eye drops for 1 week. Subjective ocular symptoms and objective ocular signs evaluated by slit-lamp examination were scored and recorded before and after treatment. Results: Both drugs significantly decreased ocular signs after 1 week, but not symptoms. No significant differences in subjective symptoms or objective signs were observed between the two drugs. Ten patients (45.5%) selected Bromfenac as more effective, nine patients (40.9%) selected Pemirolast, and three patients found no difference in efficacy between the two drugs. Conclusion: Bromfenac sodium is as safe and effective for the treatment of allergic conjunctivitis as pemirolast potassium.

Original languageEnglish
Pages (from-to)587-590
Number of pages4
JournalJapanese Journal of Ophthalmology
Volume48
Issue number6
DOIs
Publication statusPublished - 2004 Nov
Externally publishedYes

Fingerprint

pemirolast
Allergic Conjunctivitis
Potassium
Ophthalmic Solutions
Pharmaceutical Preparations
Therapeutics
Anti-Allergic Agents
Anti-Inflammatory Agents
bromfenac

Keywords

  • Allergic conjunctivitis
  • Nonsteroidal antiinflammatory drug
  • Objective ocular signs
  • Subjective ocular symptoms

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Miyake-Kashima, M., Takano, Y., Tanaka, M., Satake, Y., Kawakita, T., Dogru, M., ... Fujishima, H. (2004). Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. Japanese Journal of Ophthalmology, 48(6), 587-590. https://doi.org/10.1007/s10384-004-0127-2

Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. / Miyake-Kashima, Minori; Takano, Yoji; Tanaka, Mari; Satake, Yoshiyuki; Kawakita, Tetsuya; Dogru, Murat; Asano-Kato, Naoko; Fukagawa, Kazumi; Fujishima, Hiroshi.

In: Japanese Journal of Ophthalmology, Vol. 48, No. 6, 11.2004, p. 587-590.

Research output: Contribution to journalArticle

Miyake-Kashima, M, Takano, Y, Tanaka, M, Satake, Y, Kawakita, T, Dogru, M, Asano-Kato, N, Fukagawa, K & Fujishima, H 2004, 'Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis', Japanese Journal of Ophthalmology, vol. 48, no. 6, pp. 587-590. https://doi.org/10.1007/s10384-004-0127-2
Miyake-Kashima, Minori ; Takano, Yoji ; Tanaka, Mari ; Satake, Yoshiyuki ; Kawakita, Tetsuya ; Dogru, Murat ; Asano-Kato, Naoko ; Fukagawa, Kazumi ; Fujishima, Hiroshi. / Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. In: Japanese Journal of Ophthalmology. 2004 ; Vol. 48, No. 6. pp. 587-590.
@article{07fea81090b64db7a60afeefae1ea0f0,
title = "Comparison of 0.1{\%} bromfenac sodium and 0.1{\%} pemirolast potassium for the treatment of allergic conjunctivitis",
abstract = "Purpose: We compared the efficacy of a new nonsteroidal antiinflammatory drug (NSAID) eye drop, 0.1{\%} bromfenac sodium (Bromfenac), with that of an antiallergic agent, 0.1{\%} pemirolast potassium (Pemirolast), in the treatment of seasonal allergic conjunctivitis in Japanese patients. Methods: Twenty-two subjects with seasonal allergic conjunctivitis were enrolled in the study. One eye was treated with Bromfenac eye drops and the contralateral eye was treated with Pemirolast eye drops for 1 week. Subjective ocular symptoms and objective ocular signs evaluated by slit-lamp examination were scored and recorded before and after treatment. Results: Both drugs significantly decreased ocular signs after 1 week, but not symptoms. No significant differences in subjective symptoms or objective signs were observed between the two drugs. Ten patients (45.5{\%}) selected Bromfenac as more effective, nine patients (40.9{\%}) selected Pemirolast, and three patients found no difference in efficacy between the two drugs. Conclusion: Bromfenac sodium is as safe and effective for the treatment of allergic conjunctivitis as pemirolast potassium.",
keywords = "Allergic conjunctivitis, Nonsteroidal antiinflammatory drug, Objective ocular signs, Subjective ocular symptoms",
author = "Minori Miyake-Kashima and Yoji Takano and Mari Tanaka and Yoshiyuki Satake and Tetsuya Kawakita and Murat Dogru and Naoko Asano-Kato and Kazumi Fukagawa and Hiroshi Fujishima",
year = "2004",
month = "11",
doi = "10.1007/s10384-004-0127-2",
language = "English",
volume = "48",
pages = "587--590",
journal = "Japanese Journal of Ophthalmology",
issn = "0021-5155",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis

AU - Miyake-Kashima, Minori

AU - Takano, Yoji

AU - Tanaka, Mari

AU - Satake, Yoshiyuki

AU - Kawakita, Tetsuya

AU - Dogru, Murat

AU - Asano-Kato, Naoko

AU - Fukagawa, Kazumi

AU - Fujishima, Hiroshi

PY - 2004/11

Y1 - 2004/11

N2 - Purpose: We compared the efficacy of a new nonsteroidal antiinflammatory drug (NSAID) eye drop, 0.1% bromfenac sodium (Bromfenac), with that of an antiallergic agent, 0.1% pemirolast potassium (Pemirolast), in the treatment of seasonal allergic conjunctivitis in Japanese patients. Methods: Twenty-two subjects with seasonal allergic conjunctivitis were enrolled in the study. One eye was treated with Bromfenac eye drops and the contralateral eye was treated with Pemirolast eye drops for 1 week. Subjective ocular symptoms and objective ocular signs evaluated by slit-lamp examination were scored and recorded before and after treatment. Results: Both drugs significantly decreased ocular signs after 1 week, but not symptoms. No significant differences in subjective symptoms or objective signs were observed between the two drugs. Ten patients (45.5%) selected Bromfenac as more effective, nine patients (40.9%) selected Pemirolast, and three patients found no difference in efficacy between the two drugs. Conclusion: Bromfenac sodium is as safe and effective for the treatment of allergic conjunctivitis as pemirolast potassium.

AB - Purpose: We compared the efficacy of a new nonsteroidal antiinflammatory drug (NSAID) eye drop, 0.1% bromfenac sodium (Bromfenac), with that of an antiallergic agent, 0.1% pemirolast potassium (Pemirolast), in the treatment of seasonal allergic conjunctivitis in Japanese patients. Methods: Twenty-two subjects with seasonal allergic conjunctivitis were enrolled in the study. One eye was treated with Bromfenac eye drops and the contralateral eye was treated with Pemirolast eye drops for 1 week. Subjective ocular symptoms and objective ocular signs evaluated by slit-lamp examination were scored and recorded before and after treatment. Results: Both drugs significantly decreased ocular signs after 1 week, but not symptoms. No significant differences in subjective symptoms or objective signs were observed between the two drugs. Ten patients (45.5%) selected Bromfenac as more effective, nine patients (40.9%) selected Pemirolast, and three patients found no difference in efficacy between the two drugs. Conclusion: Bromfenac sodium is as safe and effective for the treatment of allergic conjunctivitis as pemirolast potassium.

KW - Allergic conjunctivitis

KW - Nonsteroidal antiinflammatory drug

KW - Objective ocular signs

KW - Subjective ocular symptoms

UR - http://www.scopus.com/inward/record.url?scp=12144264233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144264233&partnerID=8YFLogxK

U2 - 10.1007/s10384-004-0127-2

DO - 10.1007/s10384-004-0127-2

M3 - Article

C2 - 15592786

AN - SCOPUS:12144264233

VL - 48

SP - 587

EP - 590

JO - Japanese Journal of Ophthalmology

JF - Japanese Journal of Ophthalmology

SN - 0021-5155

IS - 6

ER -